Lai LY, Oerline MK, Caram MEV, Tsao PA, et al. Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer. J Natl Cancer Inst 2022 Apr 13. pii: 6568024. doi: 10.1093.
PMID: 35417024